-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Metformin has a favorable effect on cardiovascular outcomes in both new-onset and chronic type 2 diabetes .
Metformin Diabetic Vascular
The aim of this study was to assess changes in cardiac troponin I and T in diabetic patients treated with metformin or placebo using a post hoc analysis of the HOME trial
The HOME trial was a randomized controlled trial that included 390 patients with chronic type 2 diabetes who were randomly assigned to receive either metformin (850 mg, 3/day) or placebo, along with insulin
Of the 390 subjects, 196 received metformin and 194 received placebo
The linear mixed effects regression model of this analysis did not reveal evidence of an effect on cardiac troponin I and T levels (-8.
The study showed that metformin had no clinically relevant effect on cardiac troponin I and T levels compared with placebo
Metformin had no clinically relevant effect on cardiac troponin I and T levels compared to placebo Metformin had no clinically relevant effect on cardiac troponin I and T levels compared with placebo
Original source:
Original source:Stultiens, JMG, Top, WMC, Kimenai, DM et al.
Stultiens, JMG, Top, WMC, Kimenai, DM et al.
Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial.
Cardiovasc Diabetol 21, 49 (2022) .
https://doi.
org/10.
1186/s12933-022-01482-z.
Leave a comment here